Startups Manhattan Genomics, Preventive Revive Embryo Editing

A New Chapter in a Controversial Field

Six years after scientist He Jiankui shocked the world by announcing the birth of gene-edited babies, two little-known biotech startups are reopening one of biology's most fraught frontiers. Manhattan Genomics and Preventive have both signaled plans to pursue heritable genome editing in human embryos, a move that has quickly reignited the ethical firestorm that followed He's original experiment 1. Unlike routine gene therapies that treat existing patients, heritable editing alters DNA that would be passed down to future generations, a distinction that has long placed this kind of research in a legal and moral gray zone across much of the world 1.

The reappearance of embryo-editing ambitions matters because it forces a reckoning that the scientific community largely thought it had settled. He Jiankui's 2018 announcement drew swift international condemnation, prison time in China, and a broad informal consensus among scientists that germline editing was premature and dangerous given the state of the technology. The fact that two new ventures are now willing to revisit that territory suggests either growing confidence in CRISPR's precision or a willingness to test regulatory and ethical boundaries that much of the field had considered closed 1.

The Broader Biotech Backdrop

The embryo-editing news lands amid a period of renewed enthusiasm for biotechnology more broadly, even if the rest of the sector's momentum has little to do with germline editing itself. Wall Street analysts have been pointing to a biotech bounceback, with JPMorgan flagging Charles River Laboratories as a beneficiary of renewed investment appetite in the industry 2. Fund managers echo that optimism: Franklin Biotechnology Discovery has posted five-year annualized returns more than double those of a benchmark biotech index ETF, underscoring how selective stock-picking has outperformed the sector as a whole 4.

Artificial intelligence has become a major thread in this resurgence. Investors are increasingly viewing AI-driven drug discovery as the next growth engine for biotech, with Moderna cited as an early example of how AI tools might reshape pharmaceutical development 6. Separately, a roundup of AI drug discovery companies highlighted the emergence of "generative biology" as a buzzword at industry gatherings, reflecting hopes that AI can compress drug development timelines from years to months 5. Moderna itself has offered a real-world case study in the sector's volatility: positive trial results for a cancer vaccine sent its shares surging before investors pulled back, a reminder that even genuine scientific progress doesn't guarantee sustained market enthusiasm 7.

Reputational Risks Beyond the Lab

Not all the recent biotech headlines involve breakthroughs. A separate report raised allegations that Geetha Ramaswamy, mother of Ohio gubernatorial candidate Vivek Ramaswamy, doctored data at the biotech firm Axovant, complicating the narrative around her son's touted biotech credentials 3. Taken together with the embryo-editing developments and the AI-fueled investment story, the coverage paints a sector defined by high stakes on multiple fronts: scientific ethics, market speculation, and personal reputations all intertwined in an industry moving faster than its oversight structures.